Left Condones Use of FDA-Unapproved Drug for Lactation in Transgender “Woman”

The liberal-Left is so bent on advancing the notion that transgenderism is normal that they are willing to use an FDA-unapproved drug to maintain their façade. Transgender advocates are applauding the use of domperidone on a male-to-female transgender individual to induce lactation and breastfeed his child, even though the Food and Drug Administrationhas warned against its use for safety reasons, citing concerns about its associations with cardiac arrest and sudden death.

"Thanks to the work on induced lactation in transgender women by Dr. Tamar Reisman and nurse practitioner and program manager Zil Goldstein at the Mt. Sinai Center for transgender Medicine and Surgery, a transgender mother was not only able to breastfeed her child, but to be the baby’s exclusive food source for its first six weeks of life," reports Romper.

According to the case report, a transgender “woman” who had received hormone therapy for six years was able to produce sufficient breast milk as the sole source of nourishment for six weeks after receiving domperidone, estradiol, progesterone, and breast pumping. The patient received domperidone from Canada for off-label purposes, as the drug was initially introduced to treat gastric issues. According to Romper, using drugs for off-label purposes is common in transgender medicine.

The case report goes on to acknowledge all the health benefits associated with breastfeeding, but fails to acknowledge if the same can be said if the breastmilk comes from a transgender individual who has been administered numerous gender-transitioning chemicals and domperidone.

"The serious risks associated with domperidone include cardiac arrhythmias, cardiac arrest, and sudden death. These risks are related to the blood level of domperidone, and higher levels in the blood are associated with higher risks of these events. Concurrent use of certain commonly used drugs, such as erythromycin, could raise blood levels of domperidone and further increase the risk of serious adverse cardiac outcomes," says FDA.gov.


Source :- thenewamerican